

ASX Announcement

20th July 2016

iQ3Corp announces subsidiary IQ Capital now granted its Investment Banking License

iQ3Corp Ltd (ASX:IQ3) is pleased to announce that its fully owned subsidiary, iQ Capital, has now obtained its license to operate its New York USA, based investment banking business, dedicated to the Life Sciences and Biotechnology sector.

iQ Capital is now registered by the Securities & Exchanges Commission under the Securities Exchange Act and has been admitted to membership of the Financial Industry Regulatory Authority (FINRA).

iQ Capital will now be offering its clients the following services:

- Investment advisory
- Debt or equity offerings through public or private placement
- Financial advisory
- Mergers & Acquisitions
- Restructures
- Transaction advisory
- Pricing of securities in the debt and equity offerings
- Underwriting or selling group participant
- Syndication
- Tender offers
- Selling assets
- Trading securities on own account
- Corporate re-organization or divestitures

The CEO of IQ3, Dr. George Syrmalis said:

“Over the past year many of our team members, both here and in the USA, have worked very hard in order to make this milestone a reality.

We have been building our deal book focused on the USA markets and with iQ Capital now fully operational we can move these deals to the next level.

iQ Capital in collaboration with iQ3Corp and our APAC Business Unit in Shanghai all align in such a way that enables us to efficiently execute cross border arbitrage transactions, ultimately resulting in capital and deal flow, across USA, Australia and China connecting informed strategic investors to life science companies. Given this capability, the iQ3Corp investor relations team, on behalf of a client, will be conducting a roadshow across 7 American States over the next 2 weeks.

iQ Capital has an exclusive focus on delivering high quality, strategic advice and bespoke financial solutions to investors seeking opportunities in this dynamic life science market and to life science companies seeking strategically placed capital”.

For more information, please feel free to contact the iQ3Corp Investor Relations Team.

Email:



translating science into capital and beyond

investor.relations@iq3corp.com

Phone:
+61 2 8239 5400

About iQ3Corp Ltd:

iQ3Corp is a specialised life science corporate finance and advisory firm bridging capital with science to create the medicines of the future.